National SOP for Alzheimer's blood biomarker processing standardizes pre-analytical procedures in China
Background
Alzheimer's disease (AD) poses a significant health threat, necessitating early and accurate diagnosis, especially with the advent of disease-modifying therapies. Blood biomarker detection, including β-amyloid protein and phosphorylated tau protein, offers an accessible method for early screening, diagnosis, and monitoring. However, these crucial AD blood biomarkers are highly susceptible to pre-analytical factors, which severely compromises their reliability in clinical application and hinders comparability across different research studies. This gap underscores the urgent need for standardized procedures to ensure data quality and clinical utility.
Study Design
The Cognitive Impairment Working Group of the National Medical Quality Control Center for Neurological Diseases developed the "Standard operating procedure for pre-analytical blood biomarker processing in Alzheimer's disease (2026 edition)". This initiative was driven by the growing scientific research, testing product development, and clinical application of AD blood biomarkers in China. The group formulated the standardized operating procedure by aligning with international recommendations, integrating practical experience from Chinese blood biomarker research, and considering both clinical and research requirements. The focus was on standardizing the pre-treatment of blood samples.
Results
The "Standard operating procedure for pre-analytical blood biomarker processing in Alzheimer's disease (2026 edition)" provides a comprehensive quality control reference for the research and clinical application of AD blood biomarkers in China. It addresses the critical issue of pre-analytical variability that significantly reduces the reliability of biomarkers like β-amyloid protein and phosphorylated tau protein. The standard aims to improve the consistency and comparability of results across different studies and clinical settings. By formalizing blood sample pre-treatment protocols, the SOP directly tackles factors known to compromise biomarker integrity. This standardization is crucial for the accurate interpretation of AD blood biomarker data, supporting both diagnostic precision and therapeutic monitoring. The procedure is designed to be a foundational document for quality assurance.
The standard operating procedure (SOP) directly addresses the high susceptibility of AD blood biomarkers to pre-analytical factors, aiming to enhance their reliability and comparability in clinical and research settings.
Key Findings
- A national standard operating procedure (SOP) for pre-analytical processing of Alzheimer's disease blood biomarkers was established.
- The SOP aims to enhance the reliability and comparability of AD blood biomarker detection.
- It addresses the high susceptibility of biomarkers like β-amyloid and phosphorylated tau to pre-analytical factors.
- The standard integrates international recommendations with practical Chinese research and clinical experience.
- The SOP provides a quality control reference for AD blood biomarker research and clinical application in China.
Why It Matters
This new national standard represents a significant step forward for Alzheimer's disease diagnostics and research in China, offering a critical framework for peptide users and clinicians. Adherence to this SOP will improve the reliability and comparability of AD blood biomarker data, making early diagnosis and disease monitoring more robust. For researchers, it ensures that data generated across different labs can be more accurately compared, accelerating discovery. For clinicians, it means more dependable biomarker results, potentially leading to earlier and more precise patient management, especially with the emerging disease-modifying therapies. This protocol provides a much-needed quality control reference, moving the field closer to a universally accepted and effective diagnostic pathway.
alzheimer's disease
blood biomarkers
standard operating procedure
pre-analytical
quality control
diagnosis